496 results on '"Ballantyne, Christie M."'
Search Results
2. H DL Therapeutics -Time for a Curtain Call or Time to Reconceptualize?
- Author
-
Ballantyne, Christie M. and Narnbi, Vijay
- Subjects
- *
HDL cholesterol , *HIGH density lipoproteins - Abstract
The article focuses on the evolution of HDL therapeutics from increasing HDL cholesterol levels to enhancing cholesterol efflux capacity and reverse cholesterol transport, with recent studies, like AEGIS-II, investigating the efficacy of CSL112 infusions in reducing cardiovascular events, although questions remain regarding baseline cholesterol efflux capacity, inclusion criteria, and the timing of therapeutic effects.
- Published
- 2024
- Full Text
- View/download PDF
3. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
- Author
-
Ballantyne, Christie M., Banka, Puja, Mendez, Gustavo, Garcia, Raymundo, Rosenstock, Julio, Rodgers, Anthony, Mendizabal, Geraldine, Mitchel, Yale, and Catapano, Alberico L.
- Subjects
- *
LDL cholesterol , *PEPTIDES - Abstract
MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia. This Phase 2b, randomized, double-blind, placebo-controlled, multicenter trial aimed to evaluate the efficacy and safety of MK-0616 in participants with hypercholesterolemia. This trial was planned to include 375 adult participants with a wide range of atherosclerotic cardiovascular disease risk. Participants were assigned randomly (1:1:1:1:1 ratio) to MK-0616 (6, 12, 18, or 30 mg once daily) or matching placebo. The primary endpoints included percentage change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 8 and the proportion of participants with adverse events (AEs) and study intervention discontinuations due to AEs; participants were monitored for AEs for an additional 8 weeks after the 8-week treatment period. Of the 381 participants randomized, 49% were female, and the median age was 62 years. Among 380 treated participants, all doses of MK-0616 demonstrated statistically significant (P < 0.001) differences in least squares mean percentage change in LDL-C from baseline to Week 8 vs placebo: –41.2% (6 mg), –55.7% (12 mg), –59.1% (18 mg), and –60.9% (30 mg). AEs occurred in a similar proportion of participants in the MK-0616 arms (39.5% to 43.4%) as placebo (44.0%). Discontinuations due to AEs occurred in 2 or fewer participants in any treatment group. MK-0616 demonstrated statistically significant and robust, dose-dependent placebo-adjusted reductions in LDL-C at Week 8 of up to 60.9% from baseline and was well tolerated during 8 weeks of treatment and an additional 8 weeks of follow-up. (A Study of the Efficacy and Safety of MK-0616 [Oral PCSK9 Inhibitor] in Adults With Hypercholesterolemia [MK-0616-008]; NCT05261126) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Omega-3 Fatty Acids and Risk for Atrial Fibrillation: Big Fish or Small Fry?
- Author
-
Ballantyne, Christie M. and Jia, Xiaoming
- Subjects
- *
OMEGA-3 fatty acids , *ATRIAL fibrillation , *FISH parasites - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. HDL Therapeutics -- Time for a Curtain Call or Time to Reconceptualize?
- Author
-
Ballantyne, Christie M. and Nambi, Vijay
- Subjects
- *
HDL cholesterol , *MYOCARDIAL infarction - Abstract
The article offers information on the challenges and shifts in high-density lipoprotein (HDL) therapeutics in reducing cardiovascular disease (CVD) events. Topics include the ineffectiveness of therapies increasing HDL cholesterol levels, leading to a focus on improving HDL functionality, particularly cholesterol efflux capacity.
- Published
- 2024
- Full Text
- View/download PDF
6. Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care?
- Author
-
Ballantyne, Christie M., Varughese, Mini Grace, and Abushamat, Layla A.
- Subjects
- *
AGEISM , *MEDICAL care , *OLDER people - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Existing and emerging strategies to lower Lipoprotein(a).
- Author
-
Schwartz, Gregory G. and Ballantyne, Christie M.
- Subjects
- *
CHOLESTERYL ester transfer protein , *SMALL interfering RNA , *CARDIOVASCULAR diseases risk factors , *MONOCLONAL antibodies , *DYSLIPIDEMIA - Abstract
Abundant evidence links elevated levels of lipoprotein(a) (Lp(a)) to higher cardiovascular risk, leaving clinicians with the challenge of what measures to take to mitigate Lp(a)-associated risk. Some therapies that may reduce cardiovascular risk, such as aspirin, statins, fibrates, and ezetimibe, have little effect on Lp(a) and in some cases may even increase its concentration. Other agents that reduce levels of Lp(a), such as niacin or cholesteryl ester transfer protein inhibitors, have neutral or only slightly favorable effects on cardiovascular outcomes. The only currently available therapeutic approaches that lower Lp(a) and reduce cardiovascular risk are PCSK9 inhibitors and lipoprotein apheresis. For PCSK9 inhibitors, the magnitude of clinical benefit is associated with the baseline level of Lp(a) and appears to be associated with the degree of Lp(a) reduction. Antisense oligonucleotides and small interfering RNA agents targeting apolipoprotein(a) have the potential to reduce circulating Lp(a) concentrations by more than 70%. The results of cardiovascular outcomes trials will determine whether such substantial reductions in Lp(a) are associated with meaningful clinical benefit. [Display omitted] • Statins, ezetimibe, and fibrates reduce cardiovascular risk without substantially affecting Lp(a) levels. • Conversely, therapies such as niacin and CETP inhibitors lower Lp(a) without substantially influencing cardiovascular risk. • PCSK9 monoclonal antibodies are the first drug class to lower Lp(a) levels and substantially reduce cardiovascular risk. • The clinical benefit of PCSK9 monoclonal antibodies is associated with baseline and on-treatment levels of Lp(a). • Apheresis is an expensive and invasive means of lowering Lp(a). Observational data suggest a substantial clinical benefit. • Targeted LPA therapeutics (ASO and siRNA) substantially reduce Lp(a). Clinical efficacy is under investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Guideline-Concordant Statin Therapy Use in Secondary Prevention: Should the Medical Community Wait for Divine Intervention?
- Author
-
Virani, Salim S., Ballantyne, Christie M., and Petersen, Laura A.
- Subjects
- *
SECONDARY prevention , *STATINS (Cardiovascular agents) , *CARDIOVASCULAR disease prevention , *ANTILIPEMIC agents , *PREVENTIVE health services , *DISEASE relapse - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. REDUCTIONS IN LDL-C WITHIN THE FIRST YEAR OF TREATMENT WITH INCLISIRAN: RESULTS FROM A MULTICENTER REAL WORLD COHORT.
- Author
-
Ballantyne, Christie M., Varisco, Tyler, Graham, Timothy, Iteld, Bruce J., Serota, Harvey, McElligott, Sean, Niu, Xiaoli, Hanna, Kelly, and Van Anglen, Lucinda
- Subjects
- *
LDL cholesterol - Published
- 2024
- Full Text
- View/download PDF
10. Lowering LDL cholesterol in clinical practice: time for change?
- Author
-
Abushamat, Layla A and Ballantyne, Christie M
- Subjects
- *
LDL cholesterol - Published
- 2022
- Full Text
- View/download PDF
11. Exercise and Mortality in Heart Disease Cohorts: Meta-Analysis to Augment Available Evidence.
- Author
-
Ballantyne, Christie M. and Davis, John W.
- Subjects
- *
HEART disease related mortality , *CORONARY disease - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation.
- Author
-
Hussain, Aliza and Ballantyne, Christie M.
- Abstract
Although numerous trials have convincingly shown benefits of statin therapy in both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), most showed relative risk reductions of 25–40%, and thus many individuals continue to have ASCVD events despite statin therapy. Substantial progress has been made in developing therapies that address the residual risk for ASCVD despite statin therapy. In this review, we summarize progress of currently available therapies along with therapies under development that further reduce low-density lipoprotein cholesterol and apolipoprotein B–containing lipoproteins, reduce lipoprotein(a), reduce ASCVD events in patients with high triglycerides, and directly target inflammation to reduce ASCVD risk. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. The multifaceted life of macrophages in white adipose tissue: Immune shift couples with metabolic switch.
- Author
-
Wang, Qun, Hartig, Sean M., Ballantyne, Christie M., and Wu, Huaizhu
- Abstract
Summary White adipose tissue (WAT) is a vital endocrine organ that regulates energy balance and metabolic homeostasis. In addition to fat cells, WAT harbors macrophages with distinct phenotypes that play crucial roles in immunity and metabolism. Nutrient demands cause macrophages to accumulate in WAT niches, where they remodel the microenvironment and produce beneficial or detrimental effects on systemic metabolism. Given the abundance of macrophages in WAT, this review summarizes the heterogeneity of WAT macrophages in physiological and pathological conditions, including their alterations in quantity, phenotypes, characteristics, and functions during WAT growth and development, as well as healthy or unhealthy expansion. We will discuss the interactions of macrophages with other cell partners in WAT including adipose stem cells, adipocytes, and T cells in the context of various microenvironment niches in lean or obese condition. Finally, we highlight how adipose tissue macrophages merge immunity and metabolic changes to govern energy balance for the organism. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Statins and Your Memory: "Forget" About It?
- Author
-
Ballantyne, Christie M. and Nambi, Vijay
- Subjects
- *
STATINS (Cardiovascular agents) , *RECOLLECTION (Psychology) , *COGNITION , *DEMENTIA , *MEMORY , *COGNITION disorders , *ANTILIPEMIC agents - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.
- Author
-
Ballantyne, Christie M., Manku, Mehar S., Bays, Harold E., Philip, Sephy, Granowitz, Craig, Doyle, Ralph T., and Juliano, Rebecca A.
- Subjects
- *
FATTY acids , *SATURATED fatty acids , *OMEGA-6 fatty acids , *PALMITIC acid , *OMEGA-3 fatty acids , *OLEIC acid - Abstract
Introduction: Fatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4 g/day as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia. Methods: This was a prespecified exploratory subset analysis of the ANCHOR study, which randomized 702 statin-treated patients at increased cardiovascular risk with triglycerides 200–499 mg/dl and controlled low-density lipoprotein cholesterol (40–99 mg/dl). This analysis examined effects of icosapent ethyl 4 g/day versus placebo on fatty acid levels in plasma and RBCs using a gas chromatograph assay method with flame ionization detector. Results: In plasma, treatment with icosapent ethyl 4 g/day resulted in significant increases versus placebo in the mean concentrations of EPA (+ 635%; P < 0.0001) and its metabolite, docosapentaenoic acid n-3 (+ 143%; P < 0.0001) with no significant change in docosahexaenoic acid. Treatment with icosapent ethyl 4 g/day versus placebo also resulted in significant decreases in the omega-6 fatty acids linoleic acid (− 25%) and arachidonic acid (AA; − 31%), as well as the AA/EPA ratio (− 91%). Icosapent ethyl 4 g/day also decreased the omega-9 fatty acid oleic acid (− 29%) and the saturated fatty acids palmitic acid (− 23%) and stearic acid (− 16%) (all P < 0.0001). Results were similar for RBCs. Conclusions: Icosapent ethyl 4 g/day significantly increased EPA and produced other potentially beneficial shifts in fatty acids in plasma and RBCs versus placebo. Trial Registration: ClinicalTrials.gov Identifier, NCT01047501 Funding: Amarin Pharma Inc. Plain Language Summary: Plain language summary available for this article. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Low-Density Lipoprotein Cholesterol: Is 160 the New 190?
- Author
-
Virani, Salim S. and Ballantyne, Christie M.
- Subjects
- *
LOW density lipoproteins , *CHOLESTEROL , *ATHEROSCLEROSIS , *CARDIOVASCULAR diseases , *MORTALITY , *COMPARATIVE studies , *HIGH density lipoproteins , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research - Abstract
The article comments on the study "Longterm association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease (CVD)" by S. M. Abdullah and others in the current issue. Topics include the analyses solidify the evidence that even moderately elevated atherogenic lipoprotein levels, especially when present over a long-term followup, are associated with an increased risk of CVD death and overall mortality.
- Published
- 2018
- Full Text
- View/download PDF
17. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
- Author
-
Ballantyne, Christie M., Banach, Maciej, Mancini, G.B. John, Lepor, Norman E., Hanselman, Jeffrey C., Zhao, Xin, and Leiter, Lawrence A.
- Subjects
- *
PLACEBOS , *EZETIMIBE , *CHOLESTEROL , *LOW density lipoprotein receptors , *LIPIDS - Abstract
Abstract Background and aims Patients with hyperlipidemia who are unable to tolerate optimal statin therapy are at increased cardiovascular risk due to ongoing elevations in low-density lipoprotein cholesterol (LDL-C). The objective of CLEAR Tranquility (NCT03001076) was to evaluate the efficacy and safety of bempedoic acid when added to background lipid-modifying therapy in patients with a history of statin intolerance who require additional LDL-C lowering. Methods This phase 3, multicenter, randomized, double-blind, placebo-controlled study enrolled patients with a history of statin intolerance and an LDL-C ≥100 mg/dL while on stable lipid-modifying therapy. After a 4-week ezetimibe 10 mg/day run-in period, patients were randomized 2:1 to treatment with bempedoic acid 180 mg or placebo once daily added to ezetimibe 10 mg/day for 12 weeks. The primary endpoint was the percent change from baseline to week 12 in LDL-C. Results The study population comprised 269 patients (181 bempedoic acid, 88 placebo). Bempedoic acid added to background lipid-modifying therapy that included ezetimibe reduced LDL-C by 28.5% more than placebo (p < 0.001; −23.5% bempedoic acid, +5.0% placebo). Significant reductions in secondary endpoints, including non-high-density lipoprotein cholesterol (−23.6%), total cholesterol (−18.0%), apolipoprotein B (−19.3%), and high-sensitivity C-reactive protein (−31.0%), were observed with bempedoic acid vs. placebo (p < 0.001). Bempedoic acid was well tolerated; rates of treatment-emergent adverse events, muscle-related adverse events, and discontinuations were similar in the bempedoic acid and placebo treatment groups. Conclusions Bempedoic acid may provide an oral therapeutic option complementary to ezetimibe in statin intolerant patients who require additional LDL-C lowering. Highlights • Bempedoic acid provides additional LDL-C lowering when added to ezetimibe. • Bempedoic acid lowers atherogenic lipids and hsCRP in statin intolerant patients. • Bempedoic acid is well tolerated including a low muscle-related adverse event rate. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
- Author
-
Brinton, Eliot A., Ballantyne, Christie M., Guyton, John R., Philip, Sephy, Doyle, Ralph T., Juliano, Rebecca A., and Mosca, Lori
- Subjects
- *
DRUG therapy for hyperlipidemia , *STATINS (Cardiovascular agents) , *HYPERLIPIDEMIA , *ERYTHROCYTES , *APOLIPOPROTEINS , *CARDIOVASCULAR diseases risk factors , *DIABETES , *DRUG tolerance , *DIET therapy for heart diseases , *INFLAMMATORY mediators , *LIPIDS , *LIPOPROTEINS , *LOW density lipoproteins , *MEDICAL prescriptions , *PATIENT safety , *STATISTICS , *TRIGLYCERIDES , *WHITE people , *DATA analysis , *EICOSAPENTAENOIC acid , *RANDOMIZED controlled trials , *PREVENTION , *THERAPEUTICS - Abstract
Background: High triglycerides (TG) and diabetes mellitus type 2 (DM2) are stronger predictors of cardiovascular disease (CVD) in women than in men, but few randomized, controlled clinical trials have investigated lipid-lowering interventions in women and none have reported results specifically in women with high TG and DM2. Icosapent ethyl (Vascepa) is pure prescription eicosapentaenoic acid (EPA) ethyl ester approved at 4 g/day as an adjunct to diet to reduce TG ≥500 mg/dL. Methods: The 12-week ANCHOR trial randomized 702 statin-treated patients (73% with DM; 39% women) at increased CVD risk with TG 200–499 mg/dL despite controlled low-density lipoprotein cholesterol (LDL-C; 40–99 mg/dL) to receive icosapent ethyl 2 g/day, 4 g/day, or placebo. This post hoc analysis included 146 women with DM2 (97% white, mean age 62 years) randomized to icosapent ethyl 4 g/day (n = 74) or placebo (n = 72). Results: Icosapent ethyl significantly reduced TG (−21.5%; p < 0.0001) without increasing LDL-C and lowered other potentially atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters versus placebo. Icosapent ethyl increased EPA levels in plasma (+639%; p < 0.0001; n = 49) and red blood cells (+599%; p < 0.0001; n = 47) versus placebo. Safety and tolerability of icosapent ethyl were generally similar to placebo. Conclusion: In women with DM2 at high CVD risk with persistently high TG on statins, icosapent ethyl 4 g/day reduced potentially atherogenic parameters with safety and tolerability comparable to placebo. Potential CVD benefits of icosapent ethyl are being tested in ∼8000 men and women at high CVD risk with high TG on statins in the ongoing Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial (REDUCE-IT) cardiovascular (CV) outcome trial. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Zero Coronary Artery Calcium Score: Desirable, but Enough?
- Author
-
Hussain, Aliza, Ballantyne, Christie M., and Nambi, Vijay
- Subjects
- *
CORONARY arteries , *CALCIUM , *CORONARY disease , *CALCIUM metabolism , *CALCINOSIS , *CORONARY artery disease - Published
- 2020
- Full Text
- View/download PDF
20. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
- Author
-
Puri, Rishi, Ballantyne, Christie M., Hoogeveen, Ron C., Shao, Mingyuan, Barter, Philip, Libby, Peter, Chapman, M. John, Erbel, Raimund, Arsenault, Benoit J., Raichlen, Joel S., Nissen, Steven E., and Nicholls, Stephen J.
- Subjects
- *
LOW density lipoproteins , *ATHEROSCLEROTIC plaque , *STATINS (Cardiovascular agents) , *CORONARY disease , *ROSUVASTATIN , *ATORVASTATIN , *BIOMARKERS - Abstract
Background & aims Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients. Methods Study of coronary atheroma by intravascular ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. Baseline and follow-up Lp(a) levels were measured in 915 of the 1039 SATURN participants, and were correlated with changes in percent atheroma volume (ΔPAV). Results Mean age was 57.7 ± 8.6 years, 74% were men, 96% were Caucasian, with statin use prior to study enrolment occurring in 59.3% of participants. Baseline [median (IQR)] LDL-cholesterol (LDL-C) and measured Lp(a) levels (mg/dL) were 114 (99, 137) and 17.4 (7.6, 52.9) respectively; follow-up measures were 60 (47, 77), and 16.5 (6.7, 57.7) (change from baseline: p < 0.001, p = 0.31 respectively). At baseline, there were 676 patients with Lp(a) levels <50 mg/dL [median Lp(a) of 10.9 mg/dL], and 239 patients with Lp(a) levels ≥ 50 mg/dL [median Lp(a) of 83.2 mg/dL]. Quartiles of baseline and follow-up Lp(a) did not associate with ΔPAV. Irrespective of the achieved LDL-C (< vs. ≥70 mg/dL), neither baseline nor on-treatment (< vs. ≥median) Lp(a) levels significantly associated with ΔPAV. No significant differences were observed in ΔPAV in Lp(a) risers versus non-risers, nor in those patients with baseline or on-treatment Lp(a) levels < vs. > 50 mg/dL. Conclusions In coronary artery disease patients prescribed long-term maximally intensive statin therapy with low on-treatment LDL-C levels, measured Lp(a) levels (predominantly below the 50 mg/dL threshold) do not associate with coronary atheroma progression. Alternative biomarkers may thus associate with residual cardiovascular risk in such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials.
- Author
-
Belalcazar, L. Maria and Ballantyne, Christie M.
- Subjects
- *
DIABETES , *CARDIOVASCULAR diseases , *WEIGHT loss , *MORTALITY , *CARBOHYDRATE intolerance - Abstract
The article offers information on Look Action for Health in Diabetes (AHEAD), the largest cardiovascular disease outcomes trial of lifestyle intervention for weight reduction in diabetes mellitus. New trials of pharmacological antihyperglycemic therapies found weight loss, and reduced cardiovascular morbidity and mortality.
- Published
- 2017
- Full Text
- View/download PDF
22. Skeletal muscle inflammation and insulin resistance in obesity.
- Author
-
Huaizhu Wu, Ballantyne, Christie M., and Wu, Huaizhu
- Subjects
- *
SKELETAL muscle , *INFLAMMATION , *INSULIN resistance , *HOMEOSTASIS , *OBESITY , *DISEASES , *OBESITY complications , *ADIPOSE tissues , *ANIMALS , *GLUCOSE , *MYOSITIS , *TYPE 2 diabetes , *DISEASE complications - Abstract
Obesity is associated with chronic inflammation, which contributes to insulin resistance and type 2 diabetes mellitus. Under normal conditions, skeletal muscle is responsible for the majority of insulin-stimulated whole-body glucose disposal; thus, dysregulation of skeletal muscle metabolism can strongly influence whole-body glucose homeostasis and insulin sensitivity. Increasing evidence suggests that inflammation occurs in skeletal muscle in obesity and is mainly manifested by increased immune cell infiltration and proinflammatory activation in intermyocellular and perimuscular adipose tissue. By secreting proinflammatory molecules, immune cells may induce myocyte inflammation, adversely regulate myocyte metabolism, and contribute to insulin resistance via paracrine effects. Increased influx of fatty acids and inflammatory molecules from other tissues, particularly visceral adipose tissue, can also induce muscle inflammation and negatively regulate myocyte metabolism, leading to insulin resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
- Author
-
Ballantyne, Christie M., Bays, Harold E., Philip, Sephy, Jr.Doyle, Ralph T., Braeckman, Rene A., Stirtan, William G., Soni, Paresh N., and Juliano, Rebecca A.
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *EICOSAPENTAENOIC acid , *LOW density lipoproteins , *ETHYL esters , *CHOLESTEROL , *PLACEBOS , *STATINS (Cardiovascular agents) - Abstract
Background and aims Remnant-like particle cholesterol (RLP-C) is atherogenic and may increase atherosclerotic cardiovascular disease risk. Icosapent ethyl is a high-purity prescription eicosapentaenoic acid ethyl ester (approved as an adjunct to diet to reduce triglyceride [TG] levels in adult patients with TGs ≥500 mg/dL [≥5.65 mmol/L] at 4 g/day). In the MARINE and ANCHOR studies, icosapent ethyl reduced TG and other atherogenic lipid parameter levels without increasing low-density lipoprotein cholesterol (LDL-C) levels. This exploratory analysis evaluated the effects of icosapent ethyl on calculated and directly measured RLP-C. Methods MARINE (TGs ≥500 and ≤2000 mg/dL [≥5.65 mmol/L and ≤22.6 mmol/L]) and ANCHOR (TGs ≥200 and <500 mg/dL [≥2.26 and <5.65 mmol/L] despite statin-controlled LDL-C) were phase 3, 12-week, double-blind studies that randomized adult patients to icosapent ethyl 4 g/day, 2 g/day, or placebo. This analysis assessed median percent change from baseline to study end in directly measured (immunoseparation assay) RLP-C levels (MARINE, n = 218; ANCHOR, n = 252) and calculated RLP-C levels in the full populations. Results Icosapent ethyl 4 g/day significantly reduced directly measured RLP-C levels −29.8% ( p = 0.004) in MARINE and −25.8% ( p = 0.0001) in ANCHOR versus placebo, and also reduced directly measured RLP-C levels to a greater extent in subgroups with higher versus lower baseline TG levels, in patients receiving statins versus no statins (MARINE), and in patients receiving medium/higher-intensity versus lower-intensity statins (ANCHOR). Strong correlations were found between calculated and directly measured RLP-C for baseline, end-of-treatment, and percent change values in ANCHOR and MARINE (0.73–0.92; p < 0.0001 for all). Conclusions Icosapent ethyl 4 g/day significantly reduced calculated and directly measured RLP-C levels versus placebo in patients with elevated TG levels from the MARINE and ANCHOR studies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
- Author
-
Bays, Harold E., Ballantyne, Christie M., Jr.Doyle, Ralph T., Juliano, Rebecca A., and Philip, Sephy
- Subjects
- *
EPOXYEICOSATRIENOIC acids , *TRIGLYCERIDES , *CLINICAL trials , *HYPERTRIGLYCERIDEMIA , *PHARMACODYNAMICS , *PHARMACOKINETICS - Abstract
Icosapent ethyl is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester approved at a dose of 4 g/day as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. This post-hoc exploratory analysis examined the relationship of icosapent ethyl dose with EPA concentrations in plasma and red blood cells (RBCs) across 3 clinical studies—a phase 1 pharmacokinetic study in healthy adult volunteers and 2 pivotal phase 3 studies (MARINE and ANCHOR) in adult patients with hypertriglyceridemia—and examined the relationship between EPA levels and TG-lowering effects in MARINE and ANCHOR. In all 3 studies, icosapent ethyl produced dose-dependent increases in the concentrations of EPA in plasma and RBCs. In both MARINE and ANCHOR, these dose-dependent EPA increases correlated with the degree of TG level lowering (all P <0.01). In patients with high TG levels (≥200 mg/dL) and treated with icosapent ethyl 4 g/day, the end-of-treatment plasma and RBC EPA concentrations were >170 μg/mL and >70 μg/mL, respectively. These studies support icosapent ethyl as producing predictable dose-dependent pharmacokinetics/pharmacodynamics, with TG level lowering dependent upon icosapent ethyl dose and EPA concentrations in plasma and RBCs. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Lipoprotein(a) and Risk for Stroke and Myocardial Infarction: Why Aren't We Screening?
- Author
-
Ballantyne, Christie M
- Subjects
- *
CEREBRAL ischemia , *COMPARATIVE studies , *LIPOPROTEINS , *RESEARCH methodology , *MEDICAL cooperation , *MYOCARDIAL infarction , *RESEARCH , *STROKE , *EVALUATION research - Published
- 2019
- Full Text
- View/download PDF
26. Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study.
- Author
-
Vu, Khanh N., Ballantyne, Christie M., Hoogeveen, Ron C., Nambi, Vijay, Volcik, Kelly A., Boerwinkle, Eric, and Morrison, Alanna C.
- Subjects
- *
ALCOHOL drinking , *ATHEROSCLEROSIS risk factors , *ORGANIC compounds , *COMPUTATIONAL biology , *HEMATOLOGY - Abstract
Introduction: Health benefits of low-to-moderate alcohol consumption may operate through an improved lipid profile. A Mendelian randomization (MR) approach was used to examine whether alcohol consumption causally affects lipid levels. Methods: This analysis involved 10,893 European Americans (EA) from the Atherosclerosis Risk in Communities (ARIC) study. Common and rare variants in alcohol dehydrogenase and acetaldehyde dehydrogenase genes were evaluated for MR assumptions. Five variants, residing in the ADH1B, ADH1C, and ADH4 genes, were selected as genetic instruments and were combined into an unweighted genetic score. Triglycerides (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-c) and its subfractions (HDL2-c and HDL3-c), low-density lipoprotein cholesterol (LDL-c), small dense LDL-c (sdLDL-c), apolipoprotein B (apoB), and lipoprotein (a) (Lp(a)) levels were analyzed. Results: Alcohol consumption significantly increased HDL2-c and reduced TG, total cholesterol, LDL-c, sdLDL-c, and apoB levels. For each of these lipids a non-linear trend was observed. Compared to the first quartile of alcohol consumption, the third quartile had a 12.3% lower level of TG (p < 0.001), a 7.71 mg/dL lower level of total cholesterol (p = 0.007), a 10.3% higher level of HDL2-c (p = 0.007), a 6.87 mg/dL lower level of LDL-c (p = 0.012), a 7.4% lower level of sdLDL-c (p = 0.037), and a 3.5% lower level of apoB (p = 0.058, poverall = 0.022). Conclusions: This study supports the causal role of regular low-to-moderate alcohol consumption in increasing HDL2-c, reducing TG, total cholesterol, and LDL-c, and provides evidence for the novel finding that low-to-moderate consumption of alcohol reduces apoB and sdLDL-c levels among EA. However, given the nonlinearity of the effect of alcohol consumption, even within the range of low-to-moderate drinking, increased consumption does not always result in a larger benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
- Author
-
Rosen, Jeffrey B., Ballantyne, Christie M., Hsueh, Willa A., Jianxin Lin, Shah, Arvind K., Lowe, Robert S., and Tershakovec, Andrew M.
- Subjects
- *
METABOLIC syndrome , *INSULIN resistance , *EZETIMIBE , *SIMVASTATIN , *DRUG efficacy , *CORONARY disease - Abstract
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C ⩾40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated. (Registered at clinicaltrials.gov: NCT00409773) [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia.
- Author
-
Ballantyne, Christie M., Neutel, Joel, Cropp, Anne, Duggan, William, Wang, Ellen Q., Plowchalk, David, Sweeney, Kevin, Kaila, Nitin, Vincent, John, and Bays, Harold
- Subjects
- *
HYPERCHOLESTEREMIA treatment , *PROPROTEIN convertases , *THERAPEUTIC use of monoclonal antibodies , *SUBTILISIN inhibitors , *STATINS (Cardiovascular agents) , *PLACEBOS , *LOW density lipoproteins - Abstract
Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol (LDL-C) levels in patients with hypercholesterolemia. In this 24-week, multicenter, double-blind, placebo-controlled, dose-ranging study (NCT01592240), subjects with LDL-C levels ≥80 mg/dl on stable statin therapy were randomized to Q14 days subcutaneous placebo or bococizumab 50, 100, or 150 mg or Q28 days subcutaneous placebo or bococizumab 200 or 300 mg. Doses of bococizumab were reduced if LDL-C levels persistently decreased to ≤25 mg/dl. The primary end point was the absolute change in LDL-C levels from baseline to week 12 after placebo or bococizumab administration. Continuation of bococizumab administration through to week 24 enabled the collection of safety data over an extended period. Of the 354 subjects randomized, 351 received treatment (placebo [n = 100] or bococizumab [n = 251]). The most efficacious bococizumab doses were 150 mg Q14 days and 300 mg Q28 days. Compared with placebo, bococizumab 150 mg Q14 days reduced LDL-C at week 12 by 53.4 mg/dl and bococizumab 300 mg Q28 days reduced LDL-C by 44.9 mg/dl; this was despite dose reductions in 32.5% and 34.2% of subjects at week 10 or 8, respectively. Pharmacokinetic/pharmacodynamic model-based simulation assuming no dose reductions predicted that bococizumab would lower LDL-C levels by 72.2 and 55.4 mg/dl, respectively. Adverse events were similar across placebo and bococizumab groups. Few subjects (n = 7; 2%) discontinued treatment because of treatment-related adverse events. In conclusion, bococizumab significantly reduced LDL-C across all doses despite dose reductions in many subjects. Model-based simulations predicted greater LDL-C reduction in the absence of bococizumab dose reduction. The Q14 days regimen is being evaluated in phase 3 clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Lipid lowering with PCSK9 inhibitors.
- Author
-
Dadu, Razvan T. and Ballantyne, Christie M.
- Subjects
- *
STATINS (Cardiovascular agents) , *LOW density lipoproteins , *PROPROTEIN convertases , *ENZYMES , *LIPOPROTEINS , *METABOLISM - Abstract
Statins are the most-effective therapy currently available for lowering the LDL-cholesterol (LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin. Proprotein convertase subtilisin/ kexin type 9 (PCSK9) is an enzyme with an important role in lipoprotein metabolism. Rare gain-of-function mutations in PCSK9 lead to a high LDL-C level and premature coronary heart disease, whereas loss-of- function variants lead to a low LDL-C level and a reduced incidence of coronary heart disease. Furthermore, the PCSK9 level is increased with statin therapy through negative feedback, which promotes LDL-receptor degradation and decreases the efficacy of LDL-C lowering with statins. PCSK9 inhibition is, therefore, a rational therapeutic target, and several approaches are being pursued. In phase I, II, and III trials, inhibition of PCSK9 with monoclonal antibodies has produced an additional 50-60% decrease in the LDL-C level when used in combination with statin therapy, compared with statin monotherapy. In short-term trials, PCSK9 inhibitors were well tolerated and had a low incidence of adverse effects. Ongoing phase III trials will provide information about the long-term safety of these drugs, and their efficacy in preventing cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
30. Review of Clinical Practice Guidelines for the Management of LDL-Related Risk.
- Author
-
Morris, Pamela B., Ballantyne, Christie M., Birtcher, Kim K., Dunn, Steven P., and Urbina, Elaine M.
- Subjects
- *
LOW density lipoproteins , *ATHEROSCLEROSIS risk factors , *ETIOLOGY of diseases , *ANTILIPEMIC agents , *CARDIOVASCULAR diseases , *EVIDENCE-based medicine - Abstract
Managing risk related to low-density lipoprotein (LDL) is vital in therapy for patients at risk for atherosclerotic cardiovascular disease (ASCVD) events given its important etiologic role in atherogenesis. Despite decades of research showing reduction of ASCVD risk with multiple approaches to lowering of LDL cholesterol, there continue to be significant gaps in care with inadequate numbers of patients receiving standard of care lipid-lowering therapy. Confusion regarding implementation of the multiple published clinical practice guidelines has been identified as one contributor to suboptimal management of LDL-related risk. This review summarizes the current guidelines for reduction of LDL-related cardiovascular risk provided by a number of major professional societies, which have broad applicability to diverse populations worldwide. Statements have varied in the process and methodology of development of recommendations, the grading system for level and strength of evidence, the inclusion or exclusion of expert opinion, the suggested ASCVD risk assessment tool, the lipoproteins recommended for risk assessment, and the lipoprotein targets of therapy. The similarities and differences among important guidelines in the United States and internationally are discussed, with recommendations for future strategies to improve consistency in approaches to LDL-related ASCVD risk and to reduce gaps in implementation of evidence-based therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
- Author
-
Ballantyne, Christie M., Hoogeveen, Ron C., Raya, Joe L., Cain, Valerie A., Palmer, Mike K., and Karlson, Björn W.
- Subjects
- *
BIOMARKERS , *CHOLESTEROL , *ROSUVASTATIN , *LOW density lipoproteins , *EZETIMIBE , *SIMVASTATIN ,BLOOD lipoprotein metabolism - Abstract
Abstract: Objectives: Combination therapy may help high-risk patients achieve low-density lipoprotein cholesterol (LDL-C) goals. Impact of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg (RSV10/EZE10 and RSV20/EZE10) has not been fully characterized previously. GRAVITY (NCT00525824) compared efficacy, safety and effect on biomarkers of RSV10/EZE10 and RSV20/EZE10 vs. simvastatin 40 mg and 80 mg plus EZE10 (SIM40/EZE10 and SIM80/EZE10) in patients with coronary heart disease (CHD) or CHD risk equivalent. Methods: Adult patients (n = 833) were randomized to RSV10/EZE10, RSV20/EZE10, SIM40/EZE10 or SIM80/EZE10. Following a 6-week dietary lead-in, patients received 6 weeks' statin monotherapy followed by same statin dose plus ezetimibe for 6 more weeks. Primary endpoint was LDL-C change from baseline to 12 weeks. Results: Significantly greater (p < 0.05) reductions in LDL-C and other atherogenic lipids were observed with RSV20/EZE10 vs. SIM40/EZE10 and SIM80/EZE10 and with RSV10/EZE10 vs. SIM40/EZE10. A significantly greater proportion of patients achieved LDL-C goals of <100 mg/dl and <70 mg/dl with RSV20/EZE10 vs. SIM40/EZE10 and SIM80/EZE10 and with RSV10/EZE10 vs. SIM40/EZE10. LDL-C was reduced ∼10–14% further with combination therapy vs. monotherapy. Statin monotherapy reduced cholesterol and bile acid synthesis biomarkers, ezetimibe reduced β-sitosterol (sterol absorption marker), and combination therapy achieved additive reductions in lipoprotein-associated phospholipase A2 mass and activity, free cholesterol and 7-ketocholesterol. Safety profiles of rosuvastatin/ezetimibe and simvastatin/ezetimibe combinations were comparable. Conclusion: Co-administration of rosuvastatin 10 or 20 mg plus ezetimibe achieved significant improvements in lipid profiles in high-risk patients vs. simvastatin 40 or 80 mg plus ezetimibe. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
32. APOE Modulates the Correlation Between Triglycerides, Cholesterol, and CHD Through Pleiotropy, and Gene-by-Gene Interactions.
- Author
-
Maxwell, Taylor J., Ballantyne, Christie M., Cheverud, James M., Guild, Cameron S., Ndumele, Chiadi E., and Boerwinkle, Eric
- Subjects
- *
CHOLESTEROL , *TRIGLYCERIDES , *APOLIPOPROTEIN E genetics , *AFRICAN Americans , *EUROPEAN Americans - Abstract
Relationship loci (rQTL) exist when the correlation between multiple traits varies by genotype. rQTL often occur due to gene-by-gene (G 3 G) or gene-by-environmental interactions, making them a powerful tool for detecting G 3 G. Here we present an empirical analysis of apolipoprotein E (APOE) with respect to lipid traits and incident CHD leading to the discovery of loci that interact with APOE to affect these traits. We found that the relationship between total cholesterol (TC) and triglycerides (ln TG) varies by APOE isoform genotype in African-American (AA) and European-American (EA) populations. The e2 allele is associated with strong correlation between ln TG and TC while the e4 allele leads to little or no correlation. This led to a priori hypotheses that APOE genotypes affect the relationship of TC and/or ln TG with incident CHD. We found that APOE*TC was significant (P = 0.016) for AA but not EA while APOE*ln TG was significant for EA (P = 0.027) but not AA. In both cases, e2e2 and e2e3 had strong relationships between TC and ln TG with CHD while e2e4 and e4e4 results in little or no relationship between TC and ln TG with CHD. Using ARIC GWAS data, scans for loci that significantly interact with APOE produced four loci for African Americans (one CHD, one TC, and two HDL). These interactions contribute to the rQTL pattern. rQTL are a powerful tool to identify loci that modify the relationship between risk factors and disease and substantially increase statistical power for detecting G x G. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
33. The Editor's Roundtable: Hypertriglyceridemia.
- Author
-
Friedewald, Vincent E., Ballantyne, Christie M., Bays, Harold E., and Jones, Peter H.
- Subjects
- *
HYPERTRIGLYCERIDEMIA , *TRIGLYCERIDES , *CARDIOVASCULAR diseases risk factors , *PANCREATITIS , *CONVERSATION - Abstract
The article presents the conversation between doctors Vincent E. Friedewald, Christie M. Ballantyne, Harold E. Bays and Peter H. Jones on hypertriglyceridemia. Jones says that particle size is a surrogate measure of particle number which was controlled and drops out as a cardiovascular (CV) risk predictor. Bays states triglycerides (TG) are elevated by increased production and decreased clearance. Jones adds that hypertriglyceridemia cause pancreatitis due to an increase in serum TGs.
- Published
- 2013
- Full Text
- View/download PDF
34. Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
- Author
-
Ballantyne, Christie M., Davidson, Michael H., MacDougall, Diane E., Bays, Harold E., DiCarlo, Lorenzo A., Rosenberg, Noah L., Margulies, Janice, and Newton, Roger S.
- Subjects
- *
MEDICATION safety , *DRUG efficacy , *ADENOSINE triphosphate , *LYASES , *ADENOSINE monophosphate , *HYPERCHOLESTEREMIA , *PROTEIN kinases , *RANDOMIZED controlled trials , *PATIENTS , *THERAPEUTICS - Abstract
Objectives: The aim of this study was to assess the lipid-altering efficacy and safety of ETC-1002 in subjects with hypercholesterolemia. Background: ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and carbohydrate metabolism and may have therapeutic benefits in treating hypercholesterolemia and other cardiometabolic risk factors. Methods: This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluated patients (n = 177) with elevated low-density lipoprotein cholesterol (LDL-C) (130 to 220 mg/dl), who were stratified by baseline triglycerides (not elevated [<150 mg/dl] or elevated [150–<400 mg/dl]) and randomized to receive 40, 80, or 120 mg of ETC-1002 or placebo once daily for 12 weeks. Outcomes included changes in LDL-C (primary endpoint), other lipids, and cardiometabolic risk factors; and safety. Results: ETC-1002 40, 80, and 120 mg lowered least-squares mean ± SE LDL-C levels by 17.9 ± 2.2%, 25.0 ± 2.1%, and 26.6 ± 2.2%, respectively, versus a reduction of 2.1 ± 2.2% with placebo (all, p < 0.0001); LDL-C lowering was similar between the subgroups with nonelevated and elevated triglycerides. ETC-1002 also lowered non–high-density lipoprotein cholesterol (non–HDL-C), apolipoprotein B, and LDL particle number (all, p < 0.0001) in a dose-dependent manner; HDL-C and triglyceride levels were relatively unchanged. Post-hoc analyses suggest that ETC-1002 may have favorable effects on other cardiometabolic risk factors. The ETC-1002 and placebo groups did not demonstrate clinically meaningful differences in adverse events or other safety assessments. Conclusions: ETC-1002 significantly lowered LDL-C levels up to 27% across a broad range of baseline triglycerides and was generally safe and well tolerated. ETC-1002 has a novel mechanism of action and may be useful for reducing LDL-C. (A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides; NCT01262638) [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
- Author
-
Brinton, Eliot A., Ballantyne, Christie M., Bays, Harold E., Kastelein, John J., Braeckman, Rene A., and Soni, Paresh N.
- Subjects
- *
TYPE 2 diabetes , *TRIGLYCERIDES , *EICOSAPENTAENOIC acid , *HYPERTRIGLYCERIDEMIA , *LOW density lipoproteins , *C-reactive protein - Abstract
Background: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (⩾500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety of IPE in patients (N = 702) with residual high fasting TG levels (⩾200 and <500 mg/dL) despite having optimized low-density lipoprotein cholesterol (LDL-C) levels (⩾40 and <100 mg/dL) on statin therapy. Among patients randomized to IPE (4 g/day or 2 g/day) or placebo, 514 (73%) had diabetes mellitus. Methods: A post hoc subgroup analysis of the ANCHOR study was conducted to assess the effects of IPE on median placebo-adjusted percent change from baseline in efficacy end point parameters in 3 subgroups: total (all subjects with diabetes-overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), better-controlled diabetes (below median baseline A1c), and less-controlled diabetes (above median baseline A1c). Results: Baseline efficacy parameters were similar among all groups except high-sensitivity C-reactive protein (hsCRP), which was higher in the total and less-controlled diabetes groups. Compared with placebo, IPE 4 g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol in all 3 diabetes groups, LDL-C in the total diabetes group, and hsCRP in the total and less-controlled diabetes groups. Decreases in hsCRP and Apo B were much greater in patients with less-controlled diabetes. There were no significant increases in fasting plasma glucose, A1c, insulin, or homeostasis model assessment-estimated insulin resistance in any group. Conclusion: IPE 4 g/day significantly improved lipid and lipid-related parameters without worsening glycemic control in patients with diabetes and mixed dyslipidemia, with possibly greater effects among those with less-controlled diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
- Author
-
Ballantyne, Christie M., Pitt, Bertram, Loscalzo, Joseph, Cain, Valerie A., and Raichlen, Joel S.
- Subjects
- *
LIPOPROTEINS , *ACUTE coronary syndrome , *LOW density lipoproteins , *ROSUVASTATIN , *REGRESSION analysis , *ANALYSIS of triglycerides , *PATIENTS - Abstract
The low-density lipoprotein (LDL) cholesterol goal of <70 mg/dl, recommended for patients with acute coronary syndrome, typically requires intensive therapy with high-dose statins. The secondary goals of nonLhigh-density lipoprotein (non-HDL) cholesterol <100 mg/dl and apolipoprotein B (ApoB) <80 mg/dl have been recommended to reduce excess cardiovascular risk not captured by LDL cholesterol. The present post hoc analysis from the Limiting UNdertreatment of lipids in Acute coronary syndrome with Rosuvastatin (LUNAR) study examined the relation of ApoB with LDL cholesterol and non-HDL cholesterol at baseline and during treatment with intensive statin therapy. The LUNAR participants had acute coronary syndrome and received rosuvastatin 40 mg/day or 20 mg/day or atorvastatin 80 mg/day for 12 weeks. Linear regression analyses were used to compare ApoB, direct LDL cholesterol, and non-HDL cholesterol at baseline and during therapy. Of the 682 patients included in the analysis, 220 had triglycerides ≥200 mg/dl. Linear regression analysis showed that correlation of ApoB and non-HDL cholesterol was stronger than that of ApoB and LDL cholesterol and stronger with statin therapy than at baseline (R² = 0.93 for ApoB vs non-HDL cholesterol with statins). The target of ApoB of 80 mg/dl correlated with LDL cholesterol of 90 mg/dl and non-HDL cholesterol of 110 mg/dl at baseline and with LDL cholesterol of 74 mg/dl and non-HDL cholesterol of 92 mg/dl with statin therapy. For high-triglyceride patients, the corresponding on-treatment targets were LDL cholesterol of 68 mg/dl and non-HDL cholesterol of 92 mg/dl. In conclusion, non-HDL cholesterol is an adequate surrogate of ApoB during statin therapy, independent of triglyceride status. However, to match LDL cholesterol and ApoB treatment goals in the very-high-risk category, the current non-HDL cholesterol goal should be lowered by 8 to 10 mg/dl. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
37. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
- Author
-
Ballantyne, Christie M., Bays, Harold E., Kastelein, John J., Stein, Evan, Isaacsohn, Jonathan L., Braeckman, Rene A., and Soni, Paresh N.
- Subjects
- *
DRUG efficacy , *EICOSAPENTAENOIC acid , *ETHYL esters , *TRIGLYCERIDES , *FATTY acids , *C-reactive protein , *CHOLESTEROL , *STATINS (Cardiovascular agents) - Abstract
AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated patients with residually high triglyceride (TG) levels (≥200 and <500 mg/dl) despite low-density lipoprotein (LDL) cholesterol control (≥40 and <100 mg/dl). Patients (n = 702) on a stable diet were randomized to AMR101 4 or 2 g/day or placebo. The primary end point was median percent change in TG levels from baseline versus placebo at 12 weeks. AMR101 4 and 2 g/day significantly decreased TG levels by 21.5% (p <0.0001) and 10.1% (p = 0.0005), respectively, and non-high-density lipoprotein (non-HDL) cholesterol by 13.6% (p <0.0001) and 5.5% (p = 0.0054), respectively. AMR101 4 g/day produced greater TG and non-HDL cholesterol decreases in patients with higher-efficacy statin regimens and greater TG decreases in patients with higher baseline TG levels. AMR101 4 g/day decreased LDL cholesterol by 6.2% (p = 0.0067) and decreased apolipoprotein B (9.3%), total cholesterol (12.0%), very-low-density lipoprotein cholesterol (24.4%), lipoprotein-associated phospholipase A2 (19.0%), and high-sensitivity C-reactive protein (22.0%) versus placebo (p <0.001 for all comparisons). AMR101 was generally well tolerated, with safety profiles similar to placebo. In conclusion, AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A2, and high-sensitivity C-reactive protein in statin-treated patients with residual TG elevations. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
38. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease.
- Author
-
Nicholls, Stephen J., Ballantyne, Christie M., Barter, Philip J., Chapman, M. John, Erbel, Raimund M., Libby, Peter, Raichlen, Joel S., Uno, Kiyoko, Borgman, Marilyn, Wolski, Kathy, and Nissen, Steven E.
- Subjects
- *
STATINS (Cardiovascular agents) , *ENZYME inhibitors , *CORONARY disease , *HEART diseases , *ATHEROSCLEROSIS - Abstract
Background: Statins reduce adverse cardiovascular outcomes and slow the progression of coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) cholesterol. However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches to maximal statin administration. Methods: We performed serial intravascular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of treatment with either atorvastatin, 80 mg daily, or rosuvastatin, 40 mg daily, to compare the effect of these two intensive statin regimens on the progression of coronary atherosclerosis, as well as to assess their safety and side-effect profiles. Results: After 104 weeks of therapy, the rosuvastatin group had lower levels of LDL cholesterol than the atorvastatin group (62.6 vs. 70.2 mg per deciliter [1.62 vs. 1.82 mmol per liter], P<0.001), and higher levels of high-density lipoprotein (HDL) cholesterol (50.4 vs. 48.6 mg per deciliter [1.30 vs. 1.26 mmol per liter], P=0.01). The primary efficacy end point, percent atheroma volume (PAV), decreased by 0.99% (95% confidence interval [CI], −1.19 to −0.63) with atorvastatin and by 1.22% (95% CI, −1.52 to −0.90) with rosuvastatin (P=0.17). The effect on the secondary efficacy end point, normalized total atheroma volume (TAV), was more favorable with rosuvastatin than with atorvastatin: −6.39 mm3 (95% CI, −7.52 to −5.12), as compared with −4.42 mm3 (95% CI, −5.98 to −3.26) (P=0.01). Both agents induced regression in the majority of patients: 63.2% with atorvastatin and 68.5% with rosuvastatin for PAV (P=0.07) and 64.7% and 71.3%, respectively, for TAV (P=0.02). Both agents had acceptable side-effect profiles, with a low incidence of laboratory abnormalities and cardiovascular events. Conclusions: Maximal doses of rosuvastatin and atorvastatin resulted in significant regression of coronary atherosclerosis. Despite the lower level of LDL cholesterol and the higher level of HDL cholesterol achieved with rosuvastatin, a similar degree of regression of PAV was observed in the two treatment groups. (Funded by AstraZeneca Pharmaceuticals; ClinicalTrials.gov number, NCT000620542.) [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
39. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
- Author
-
Bays, Harold E., Ballantyne, Christie M., Kastelein, John J., Isaacsohn, Jonathan L., Braeckman, Rene A., and Soni, Paresh N.
- Subjects
- *
BLOOD disease treatment , *ESTERS , *EICOSAPENTAENOIC acid , *TRIGLYCERIDES , *PLACEBOS , *RANDOMIZED controlled trials , *DOCOSAHEXAENOIC acid , *LOW density lipoproteins , *FISH oils , *THERAPEUTICS - Abstract
AMR101 is an omega-3 fatty acid agent containing ≥96% eicosapentaenoic acid ethyl ester and no docosahexaenoic acid. Previous smaller studies suggested that highly purified eicosapentaenoic acid lowered triglyceride (TG) levels without increasing low-density lipoprotein (LDL) cholesterol levels. TG-lowering therapies such as fibrates, and fish oils containing both eicosapentaenoic acid and docosahexaenoic acid, can substantially increase LDL cholesterol levels when administered to patients with very high TG levels (≥500 mg/dl). The present double-blind study randomized 229 diet-stable patients with fasting TG ≥500 mg/dl and ≤2,000 mg/dl (with or without background statin therapy) to AMR101 4 g/day, AMR101 2 g/day, or placebo. The primary end point was the placebo-corrected median percentage of change in TG from baseline to week 12. The baseline TG level was 680, 657, and 703 mg/dl for AMR101 4 g/day, AMR101 2 g/day, and placebo. AMR101 4 g/day reduced the placebo-corrected TG levels by 33.1% (n = 76, p <0.0001) and AMR101 2 g/day by 19.7% (n = 73, p = 0.0051). For a baseline TG level >750 mg/dl, AMR101 4 g/day reduced the placebo-corrected TG levels by 45.4% (n = 28, p = 0.0001) and AMR101 2 g/day by 32.9% (n = 28, p = 0.0016). AMR101 did not significantly increase the placebo-corrected median LDL cholesterol levels at 4 g/day (−2.3%) or 2 g/day (+5.2%; both p = NS). AMR101 significantly reduced non–high-density lipoprotein cholesterol, apolipoprotein B, lipoprotein-associated phospholipase A2, very low-density lipoprotein cholesterol, and total cholesterol. AMR101 was generally well tolerated, with a safety profile similar to that of the placebo. In conclusion, the present randomized, double-blind trial of patients with very high TG levels demonstrated that AMR101 significantly reduced the TG levels and improved other lipid parameters without significantly increasing the LDL cholesterol levels. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
40. The Editor's Roundtable: JUPITER Follow-Up
- Author
-
Friedewald, Vincent E., Ballantyne, Christie M., Davidson, Michael H., Gotto, Antonio M., Ridker, Paul M., and Roberts, William C.
- Published
- 2011
- Full Text
- View/download PDF
41. Pharmacological strategies for lowering LDL cholesterol: statins and beyond.
- Author
-
Brautbar, Ariel and Ballantyne, Christie M.
- Subjects
- *
LOW density lipoproteins , *STATINS (Cardiovascular agents) , *CHOLESTEROL , *CARDIOVASCULAR diseases risk factors , *PHARMACOLOGY , *CARDIOVASCULAR disease prevention , *DRUG therapy for hyperlipidemia , *ANTILIPEMIC agents , *COMBINATION drug therapy , *ANIMAL experimentation , *LDL cholesterol , *CARDIOVASCULAR diseases , *HYPERLIPIDEMIA , *RISK assessment , *MEDICAL protocols , *TREATMENT effectiveness , *DISEASE complications - Abstract
A continuous, graded relationship exists between LDL cholesterol (LDL-C) levels and risk of cardiovascular disease (CVD). This finding has been confirmed at progressively lower levels of LDL-C by results from clinical trials of therapies, particularly high-potency statins, which provide increasingly greater reductions in LDL-C levels. On the basis of this clinical trial evidence, progressively lower LDL-C goals for increasing numbers of patients, stratified by absolute CVD risk, have been recommended in guidelines for cholesterol management and CVD prevention. Some notable exceptions have been made, however, such as patients with end-stage renal disease or heart failure. To achieve low LDL-C goals, statins are first-line pharmacological therapy and can be combined with other agents to provide additional reductions in LDL-C levels as well as improvements in other lipoprotein fractions. Investigational agents that reduce LDL-C levels by other mechanisms are under development and could provide additional therapeutic strategies to achieve optimal LDL-C levels. These agents could be particularly appropriate for patients with severely elevated LDL-C levels, such as those with genetic dyslipidemia, for whom maximal drug therapy is insufficient to reduce LDL-C concentrations to recommended levels. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
42. Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)
- Author
-
Robinson, Jennifer G., Ballantyne, Christie M., Grundy, Scott M., Hsueh, Willa A., Parving, Hans-Henrik, Rosen, Jeffrey B., Adewale, Adeniyi J., Polis, Adam B., Tomassini, Joanne E., and Tershakovec, Andrew M.
- Subjects
- *
DRUG efficacy , *STATINS (Cardiovascular agents) , *HYPERCHOLESTEREMIA , *DRUG dosage , *METABOLIC syndrome , *CARDIOVASCULAR diseases risk factors , *C-reactive protein , *MEDICATION safety , *PATIENTS - Abstract
Patients with the metabolic syndrome are at an increased risk of cardiovascular disease and might require intensive lipid therapy. Many patients remain at the starting dose of lipid therapy and might not be titrated up to a higher dose. The present double-blind, randomized, 6-week study assessed the lipid-lowering efficacy of ezetimibe/simvastatin 10/20 mg versus atorvastatin 10 or 20 mg, and ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in 1,128 patients with hypercholesterolemia and the metabolic syndrome. The primary end point was the percentage of change from baseline in low-density lipoprotein (LDL) cholesterol. Additional end points included changes in other lipids, lipoprotein ratios, high-sensitivity C-reactive protein, and attainment of prespecified lipid levels. Significantly greater improvements in the levels of LDL cholesterol, non–high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios resulted with ezetimibe/simvastatin compared with atorvastatin at all specified dose comparisons (p <0.001). The attainment of prespecified LDL cholesterol and non–high-density lipoprotein cholesterol levels was also significantly greater with ezetimibe/simvastatin than with atorvastatin at all dose comparisons (p <0.05). High-density lipoprotein cholesterol increases were significantly greater with ezetimibe/simvastatin 10/20 mg than with atorvastatin 10 mg (p <0.05) and ezetimibe/simvastatin 10/40 mg than with atorvastatin 40 mg (p <0.01). The changes in triglycerides, very low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein were similar for both treatments. The incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events were low and generally similar to those in previous studies of ezetimibe/simvastatin and/or atorvastatin. In conclusion, ezetimibe/simvastatin was more likely to result in lipid treatment end points than atorvastatin and was generally well tolerated at the doses compared in our patients. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
43. Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy
- Author
-
Pearson, Thomas A., Ballantyne, Christie M., Veltri, Enrico, Shah, Arvind, Bird, Steven, Lin, Jianxin, Rosenberg, Elizabeth, and Tershakovec, Andrew M.
- Subjects
- *
C-reactive protein , *LOW density lipoproteins , *CORONARY disease , *BLOOD cholesterol , *STATINS (Cardiovascular agents) , *PLACEBOS , *STATISTICAL correlation , *INFLAMMATION - Abstract
Inflammation is associated with coronary artery disease (CAD), and statins reduce the inflammatory marker C-reactive protein (CRP). The effects of ezetimibe, alone or in combination with statins, on CRP and low-density lipoprotein (LDL) cholesterol were examined in 2 pooled analyses of randomized, placebo-controlled trials of ezetimibe 10 mg/day in patients with hypercholesterolemia: 6 12-week trials as monotherapy (n = 1,372) and 7 6- to 8-week trials as add-on to baseline statin therapy (n = 3,899). Mean percentage changes from baseline in CRP and LDL cholesterol were examined using analysis of variance in patients with CRP ≤10 mg/L. Effects within subgroups (age, gender, race, body mass index, diabetes mellitus, metabolic syndrome, CAD, baseline CRP or lipids, and statin potency) and correlations between CRP and LDL cholesterol were also examined. Reduction in CRP by ezetimibe monotherapy was numerically greater than with placebo (treatment difference 6%, p = 0.09). Added to statin therapy, ezetimibe was associated with a significant additional reduction in CRP (treatment difference 10%, p <0.001). Treatment effects were generally consistent across subgroups for the 2 analyses. With monotherapy and add-on to statin therapy, LDL cholesterol reduction with ezetimibe was significantly greater than with placebo (treatment differences −19% and −23%, respectively, p <0.001). Spearman''s correlation coefficients among baseline values and percentage changes from baseline in CRP and LDL cholesterol ranged from −0.007% to 0.13%. In conclusion, the addition of ezetimibe to statin treatment provides significantly enhanced CRP reductions over and above those achieved with statin monotherapy. Correlations between changes in CRP and changes in LDL cholesterol were weakly positive and significant only when ezetimibe was added to statin treatment. The effects of ezetimibe monotherapy are not well defined. The effects of ezetimibe on CRP were consistent across patient subgroups. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
44. How to identify patients with vulnerable plaques.
- Author
-
Virani, Salim S. and Ballantyne, Christie M.
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *C-reactive protein , *LIPOPROTEINS , *PHOSPHOLIPASES , *BIOMARKERS , *PHYSIOLOGY , *THERAPEUTICS - Abstract
Multiple strategies are available for clinicians to identify patients at high risk for cardiovascular events. Two commonly discussed strategies are the identification of vulnerable plaques and the identification of vulnerable patients. The strategy of identifying vulnerable patients is less invasive, easy to implement and not restricted primarily to one vascular bed (e.g. coronary or cerebral). This review discusses the utility as well as the limitations of global risk assessment tools to identify such patients. The utility of biomarkers [C-reactive protein, lipoprotein-associated phospholipase A2 and lipoprotein(a)] and non-invasive measures of atherosclerosis burden (coronary artery calcium scores, carotid intima–media thickness and ankle–brachial index) in identifying patients at high risk for cardiovascular events are also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
45. The Editor's Roundtable: Lipid Management Beyond Statins—Reducing Residual Cardiovascular Risk
- Author
-
Friedewald, Vincent E., Ballantyne, Christie M., Davidson, Michael H., Guyton, John R., and Roberts, William C.
- Published
- 2008
- Full Text
- View/download PDF
46. Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial
- Author
-
Ballantyne, Christie M., Raichlen, Joel S., and Cain, Valerie A.
- Subjects
- *
APOLIPOPROTEIN B , *LIPOPROTEINS , *CORONARY disease - Abstract
Objectives: The purpose of this analysis was to compare concentrations of low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apoB) before and during statin therapy. Background: Reducing LDL-C to a pre-determined goal may still leave an excess of atherogenic lipoproteins, as reflected in apoB levels. Methods: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial examined the effects of statin treatment in patients with high coronary heart disease (CHD) risk, LDL-C ≥130 and <250 mg/dl, and triglycerides <400 mg/dl. Therapy consisted of rosuvastatin (10 or 20 mg), atorvastatin (10 or 20 mg), or simvastatin (20 or 40 mg). The apoB and LDL-C or non–HDL-C at baseline and after 16 weeks of therapy were compared using linear regression. Results: In untreated patients, the apoB target of <90 mg/dl was roughly equivalent to an LDL-C level <100 mg/dl and a non–HDL-C level <130 mg/dl, which is consistent with existing apoB and lipoprotein guidelines. However, during statin therapy, to reach an apoB target of <90 mg/dl it was necessary to reduce non–HDL-C to <100 mg/dl or to reduce LDL-C to <70 mg/dl (in high-triglyceride patients) or <80 mg/dl (in lower-triglyceride patients). The tight correlation seen for non–HDL-C with apoB while on statin therapy (R2 = 0.92) implies that non–HDL-C may be an acceptable surrogate for direct apoB measurement. Conclusions: These data are consistent with the more aggressive cholesterol goals suggested for CHD patients, because achieving such targets also reduced apoB to the recommended level. (Mercury II–Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia; NCT00654407) [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
47. Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (from the SEACOAST I Study)
- Author
-
Ballantyne, Christie M., Davidson, Michael H., McKenney, James, Keller, Laurence H., Bajorunas, Daiva R., and Karas, Richard H.
- Subjects
- *
NIACIN , *ISOPENTENOIDS , *TRIGLYCERIDES , *HYPERTRIGLYCERIDEMIA - Abstract
The efficacy and safety of 2 regimens of a combination of a proprietary niacin extended release plus simvastatin (NER/S; 1,000/20 and 2,000/20 mg/day) were compared with simvastatin monotherapy (20 mg/day) for 24 weeks in 319 high-risk patients with predominantly mixed dyslipidemia who were already at National Cholesterol Education Program Adult Treatment Panel III risk-adjusted goals for low-density lipoprotein cholesterol. After a run-in on simvastatin 20 mg/day, both NER/S doses (1,000/20 and 2,000/20 mg/day) resulted in greater decreases in non–high-density lipoprotein (HDL) cholesterol vs simvastatin 20 mg/day (−13.9% and −22.5% vs −7.4%, respectively; p <0.01). Significant improvements in HDL cholesterol, triglycerides, apolipoprotein B, lipoprotein(a), and total/HDL cholesterol ratio were also observed. Patients with hypertriglyceridemia (triglycerides ≥200 mg/dl) typically had greater lipid responses to NER/S with the notable exception that HDL cholesterol responses to NER/S were similar in those with or without increased triglycerides. Treatment with both doses of NER/S was well tolerated; ≤60% of patients in any treatment group experienced flushing, >90% of flushing was mild or moderate in intensity, and only 7.5% of patients in both NER/S treatment groups discontinued because of flushing. The safety of NER/S was consistent with the safety profile of each individual component. In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
48. The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
- Author
-
Mohler, Emile R., Ballantyne, Christie M., Davidson, Michael H., Hanefeld, Markolf, Ruilope, Luis M., Johnson, Joel L., and Zalewski, Andrew
- Subjects
- *
BLOOD lipoproteins , *CORONARY disease , *PHOSPHOLIPASES , *BIOMARKERS - Abstract
Objectives: This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, on biomarkers of cardiovascular (CV) risk. Background: Elevated Lp-PLA2 levels are associated with an increased risk of CV events. Methods: Coronary heart disease (CHD) and CHD-risk equivalent patients (n = 959) receiving atorvastatin (20 or 80 mg) were randomized to oral darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. Blood samples were analyzed for Lp-PLA2 activity and other biomarkers. Results: Baseline low-density lipoprotein cholesterol (LDL-C) was 67 ± 22 mg/dl. Plasma Lp-PLA2 was higher in older patients (≥75 years), in men, in those taking atorvastatin 20 mg, at LDL-C ≥70 mg/dl or high-density lipoprotein cholesterol (HDL-C) <40 mg/dl, or in those with documented vascular disease (multivariate regression; p < 0.01). Darapladib 40, 80, and 160 mg inhibited Lp-PLA2 activity by approximately 43%, 55%, and 66% compared with placebo (p < 0.001 weeks 4 and 12). Sustained dose-dependent inhibition was noted overall in both atorvastatin groups and at different baseline LDL-C (≥70 vs. <70 mg/dl) and HDL-C (<40 vs. ≥40 mg/dl). At 12 weeks, darapladib 160 mg decreased interleukin (IL)-6 by 12.3% (95% confidence interval [CI] −22% to −1%; p = 0.028) and high-sensitivity C-reactive protein (hs-CRP) by 13.0% (95% CI −28% to +5%; p = 0.15) compared with placebo. The Lp-PLA2 inhibition produced no detrimental effects on platelet biomarkers (P-selectin, CD40 ligand, urinary 11-dehydrothromboxane B2). No major safety concerns were noted. Conclusions: Darapladib produced sustained inhibition of plasma Lp-PLA2 activity in patients receiving intensive atorvastatin therapy. Changes in IL-6 and hs-CRP after 12 weeks of darapladib 160 mg suggest a possible reduction in inflammatory burden. Further studies will determine whether Lp-PLA2 inhibition is associated with favorable effects on CV events. (SB-480848 in Subjects With Coronary Heart Disease; NCT00269048) [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
49. The Editor’s Roundtable: Atherosclerosis Regression
- Author
-
Friedewald, Vincent E., Ballantyne, Christie M., Nissen, Steven E., Shah, P.K., and Roberts, William C.
- Published
- 2008
- Full Text
- View/download PDF
50. Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins
- Author
-
Stein, Evan A., Ballantyne, Christie M., Windler, Eberhard, Sirnes, Per Anton, Sussekov, Andrey, Yigit, Zerrin, Seper, Claudia, and Gimpelewicz, Claudio R.
- Subjects
- *
STATINS (Cardiovascular agents) , *DRUG side effects , *MUSCLE diseases , *THERAPEUTICS - Abstract
Although statin treatment is generally well tolerated, it is estimated that 5% to 10% of patients develop muscle-related side effects (MRSEs), resulting in less effective nonstatin alternatives or cessation of lipid-lowering therapy completely. This study was designed to assess the efficacy and tolerability of extended-release fluvastatin (fluvastatin XL) and ezetimibe alone or in combination in patients with previous MRSEs with other statins. This was a double-blinded, double-dummy trial of 199 mostly moderate- or high-risk dyslipidemic patients randomized to fluvastatin XL 80 mg/day (n = 69), ezetimibe 10 mg/day (n = 66), or fluvastatin XL 80 mg/day plus ezetimibe 10 mg/day (n = 64) for 12 weeks. Fluvastatin XL lowered low-density lipoprotein (LDL) cholesterol by 32.8% compared with 15.6% with ezetimibe (between-group difference −17.1%, 95% confidence interval −23.6 to −10.7, p <0.0001); the fluvastatin XL/ezetimibe combination lowered LDL cholesterol by 46.1% (between-group difference vs ezetimibe −30.4%, 95% confidence interval −37.0 to −23.8, p <0.0001). Proportions of patients achieving their National Cholesterol Education Program Adult Treatment Panel III target LDL cholesterol were 84% with the fluvastatin XL/ezetimibe combination, 59% with fluvastatin XL, and 29% with ezetimibe (p <0.001 for fluvastatin XL monotherapy or combination therapy vs ezetimibe monotherapy). Incidences of MRSEs were 24% in the ezetimibe group, 17% in the fluvastatin XL group, and 14% in the combination group. There were no instances of creatine kinase increases ≥10 times upper limit of normal. In conclusion, in patients with a history of statin-associated MRSEs, fluvastatin XL alone or in combination with ezetimibe offers an effective and well-tolerated lipid-lowering option. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.